

- **Name:** Changsong Qi
- **Current Position & Affiliation:** Deputy chief physician, Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute, Beijing
- **Country:** China

• **Educational Background:**

Sep.2006-Jul.2014 Doctor of Medicine (MD), Peking University, Beijing, China

• **Professional Experience:**

Apr.2011-Mar.2012	Internship (internal medicine) Peking University Third Hospital, Beijing, China
Apr.2012- Nov.2019	Residency Training (internal medicine and GI medical oncology) Peking University Third Hospital, Beijing Hospital, Beijing Cancer Hospital, Beijing, China
Nov.2019-Aug. 2022	Attending Physician (GI medical oncology) Peking University Cancer Hospital, Beijing Cancer Hospital & Institute, Beijing, China
Aug. 2022-Present	Deputy Chief Physician (Department of Early Drug Development Centre) Peking University Cancer Hospital, Beijing Cancer Hospital & Institute, Beijing, China

• **Professional Organizations:**

Member of American Society of Clinical Oncology (ASCO)

Member of European Society for Medical Oncology (ESMO)

Member of Chinese Society of Clinical Oncology (CSCO)

• **Main Scientific Publications:**

- **Changsong Qi#***, Chang Liu#, Zhi Peng#, Yanqiao Zhang#, Jia Wei#, Wensheng Qiu#, Xiaotian Zhang, Hongming Pan, Zuoxing Niu, Meng Qiu, Yanru Qin, Weijia Fang, Feng Ye, Ning Li, Tianshu Liu, Anwen Liu, Xizhi Zhang, Changlu Hu, Jun Zhang, Jiuwei Cui, Xiaoyan Lin, Shubin Wang, Jian Zhang, Tongyu Lin, Xiujuan Qu, Xianglin Yuan, Jifang Gong, Jian Li, Wanwan Gao, Lun Gai, Yumeng Wang, Daijing Yuan, Zonghai Li, Lin Shen*. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. *Lancet*. 2025 Jun 7;405(10494):2049-2060.
- **Changsong Qi#***, Chang Liu#, Jifang Gong#, Dan Liu, Xicheng Wang, Panpan Zhang, Yanru Qin, Sai Ge, Miao Zhang, Zhi Peng, Jun Zhou, Zhihao Lu, Ming

Lu, Yanshuo Cao, Jiajia Yuan, Yakun Wang, Zhenghang Wang, Ran Xue, Xiaohui Peng, Yumeng Wang, Daijing Yuan, Jian Li*, Xiaotian Zhang*, Lin Shen*.

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. *Nat Med*, 2024 Aug;30(8):2224-2234.

- **Changsong Qi#**, Jifang Gong#, Jian Li#, Dan Liu, Yanru Qin, Sai Ge, Miao Zhang, Zhi Peng, Jun Zhou, Yanshuo Cao, Xiaotian Zhang, Zhihao Lu, Ming Lu, Jiajia Yuan, Zhenghang Wang, Yakun Wang, Xiaohui Peng, Huiping Gao, Zhen Liu, Huamao Wang, Daijing Yuan, Jun Xiao, Hong Ma, Wei Wang, Zonghai Li, Lin Shen*. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. *Nat Med*, 2022 Jun;28(6):1189-1198.
- **Changsong Qi#***, Panpan Zhang#, Chang Liu, Jun Zhang, Jun Zhou, Jiajia Yuan, Dan Liu, Miao Zhang, Jifang Gong, Xicheng Wang, Jian Li, Xiaotian Zhang, Ning Li, Xiaohui Peng, Zhen Liu, Daijing Yuan, Raffaele Baffa, Yumeng Wang, Lin Shen. Safety and Efficacy of CT041 in Patients with Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials. *Journal of Clinical Oncology*, 2024 Jul 20;42(21):2565-2577.
- **Changsong Qi #***, Dongqun Liu #, Chang Liu #, Xiaofei Wei, Mingyang Ma, Xinan Lu, Min Tao, Cheng Zhang, Xicheng Wang, Ting He, Jian Li, Fei Dai, Yanping Ding, Lin Shen*. Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells. *J Immunother Cancer*. 2024 Oct 4;12(10): e009960.
- **Changsong Qi#**; Tong Xie#; Jun Zhou#; Xicheng Wang; Jifang Gong; Xiaotian Zhang; Jian Li; Jiajia Yuan; Chang Liu; Lin Shen*. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer, *Journal of Hematology & Oncology*, 2023, 16(1): 102-102.
- **Changsong Qi#***, Ting Zhou#, Yuezong Bai#, Hui Chen, Jiajia Yuan, Feilong Zhao, Chang Liu, Mingyang Ma, Ting Bei, Shiqing Chen, Xiaochen Zhao, Chunzhu Chen, Lin Shen*. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment. *Int J Cancer*, 2023 Dec 1;153(11):1916-1927.
- **Changsong Qi#**, Xiaoyi Chong#, Ting Zhou#, Mingyang Ma, Jifang Gong, Miao Zhang, Jian Li, Jun Xiao, Xiaohui Peng, Zhen Liu, Zonghai Li, Lin Shen, Xiaotian Zhang*. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study, *Chin J Cancer Res*. 2024 Feb 29;36(1):78-89.
- **Changsong Qi#**, Rui Guo#, Yan Chen#, Chenzhen Li#, Chang Liu, Miao Zhang, Cheng Zhang, Xiaotian Zhang, Xingguo Hou, Bo Chen, Bing Jia, Zhi Yang, Lin Shen*, Hua Zhu*. 68Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients, *J Nucl Med*. 2024 Jun 3;65(6):856-863.

- **Changsong Qi#***, Lin Shen, Thierry Andre, Hyun Cheol Chung, Timothy L Cannon, Elena Garralda, Antoine Italiano, Damian T Rieke, Tianshu Liu, Domnita-Ileana Burcoveanu, Natascha Neu, Chiara E Mussi, Rui-Hua Xu, David S Hong, Alexander Drilon, Jordan Berlin. Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. *Eur J Cancer*. 2025 Mar 4;220:115338.
- Mingyang Ma, Chang Liu, Lei Jiang, Dan Liu, Panpan Zhang, Min Tao, Miao Zhang, Jifang Gong, Zhi Peng, Xiaotian Zhang, Jian Li, Chunhong Zheng, Mi Deng, Lin Shen, **Changsong Qi***. Exploring the therapeutic efficacy difference in claudin18.2-targeted cell therapy revealed by single-cell sequencing. *iScience*. 2025 Jan 7;28(2):111768.
- Jiarui Li#, Min Tao#, Lian Liu#, Chang Liu, Mingyang Ma, Dan Liu, Panpan Zhang, Miao Zhang, Ran Xue, Jifang Gong, Cheng Zhang, Xiaotian Zhang*, Lin Shen*, **Changsong Qi***. Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer. *Br J Cancer*. 2025 Apr 17.
- Shujing Wang#, **Changsong Qi#**, Jin Ding#, Dan Li, Miao Zhang, Congcong Ji, Fangli Jiang, Fei Teng, Jie Yu, Xueming Qian, Feng Wang, Lin Shen, Jing Gao, Zhi Yang, Cheng Zhang, Hua Zhu. First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection. *Eur J Nucl Med Mol Imaging*. 2023 Apr 26.
- Izuma Nakayama#, **Changsong Qi#**, Yang Chen, Yoshiaki Nakamura, Lin Shen*, Kohei Shitara*. Claudin 18.2 as a novel therapeutic target, *Nat Rev Clin Oncol*. 2024 May;21(5):354-369.